BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy

BRAF and MEK inhibitors have improved clinical outcomes in advanced, BRAF(V600)-mutated melanomas. Acquired resistance occurs in most patients, with numerous and diverse drivers. We obtained pre-treatment and progression biopsies from a patient who progressed on dabrafenib and trametinib. In additio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pigment Cell Melanoma Res
Main Authors: Johnson, Douglas B., Childress, Merrida A., Chalmers, Zachary R., Frampton, Garrett M., Ali, Siraj M., Rubinstein, Samuel M., Fabrizio, David, Ross, Jeffrey S., Balasubramanian, Sohail, Miller, Vincent A., Stephens, Philip J., Sosman, Jeffrey A., Lovly, Christine M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5889338/
https://ncbi.nlm.nih.gov/pubmed/29171936
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12674
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados